Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
Precision-T
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- NCT05316701 ↗
- Active, not recruiting
- Orca Biosystems, Inc.
- Deep
We haven't built an HCP commentary report on Precision-T (Orca-T in advanced hematologic malignancies) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on Precision-T so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 14 | |
| YouTube | 13 | |
| Podcasts | 12 | |
| Bluesky threads | 4 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase III Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Acute Myeloid Leukemia; Acute Lymphoid Leukemia; Mixed Phenotype Acute Leukemia; Undifferentiated Leukemia; Myelodysplastic Syndrome; Acute Leukemia; Therapy-Related Myelodysplastic Syndrome
- Interventions
- Orca-T; Standard-of-Care
- Arms
- Orca-T · Experimental
- Standard of Care alloHCT Control · Active comparator
- Enrollment
- 187
- Primary outcomes
- Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC)
- Sponsor
- Orca Biosystems, Inc.
- Start
- Jun 21, 2022
- Primary completion
- Jul 15, 2024
- Results posted
- Yes
- Registry record
- NCT05316701 · updated Mar 4, 2026
Publications
linked from the registry- Meyer EH, Salhotra A, Gandhi AP, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand R, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau J, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian MS, Li A, Negrin RS, Oliai C. Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. Blood. 2026 Mar 12;147(11):1168-1177. doi: 10.1182/blood.2025031313. PubMed 41385341
- Faramand R, McClellan JS, Pavlova A, Manghani R, Blank A, Saeedian M, Yadav S, Perales MA. Cost-effectiveness of Orca-T vs allo-HCT with conventional GVHD prophylaxis for the treatment of advanced hematologic malignancies in the United States. J Med Econ. 2026 Dec;29(1):2386-2405. doi: 10.1080/13696998.2026.2732644. Epub 2026 Sep 29. PubMed 42806776